Exegenesis Bio

Focus: Exegenesis Bio is a China-based biotechnology company specializing in gene therapy, with a clinical focus on oncology and ophthalmology (age-related macular degeneration). The company is in early-stage clinical development with a minimal public footprint.

Oncology Gene Therapy

Profile data last refreshed 13h ago · AI intelligence enriched 13h ago

Open Jobs

About Exegenesis Bio

AI assessmentNot Hiring

No open roles listed right now. Follow Exegenesis Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

EXG102-031

Neovascular (Wet) Age-related Macular Degeneration (nAMD)

Phase 1

Clinical Trials (1)

NCT05903794A Study of EXG102-031 in Patients With wAMD (Everest)

Phase 1

Help build intelligence for Exegenesis Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in gene therapy, a high-growth modality with significant unmet medical need in oncology and retinal disease.
China-based position offers exposure to one of the world's fastest-growing biotech markets and potential first-mover advantages in Asian markets.
Early-stage pipeline allows direct impact on program development and clinical strategy before commercial maturity.

Watch Out For

Minimal hiring activity (zero active job openings) suggests the company is either dormant, private with lean operations, or not actively recruiting externally.
No disclosed funding, revenue, or employee count creates opacity on financial stability, runway, and career progression paths.
Only two Phase 1 programs with no Phase 2/3 advancement signals early technical or commercial risk; no publications or public clinical data to validate science.

Generated by Claude from Exegenesis Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Aflibercept

Neovascular Age-Related Macular Degeneration (nAMD)

Phase 1

Clinical Trials (1)

NCT06817343A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Ophthalmology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Ophthalmology

2 pipeline

Marketed

Pipeline

Visa Sponsorship

H-1B Petitions (FY2023)

Approved

Denied

Rate

Source: USCIS H-1B Employer Data Hub